NCT05895812View on ClinicalTrials.gov

A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

August 25, 2023

Study Completion Date

August 28, 2023

Conditions
Subjects With Renal ImpairmentHealthy Subjects
Interventions
DRUG

Deuremidevir Hydrobromide Tablets

JT001 single dose, 0.3g

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
collaborator

Sponsor GmbH

OTHER

lead

Shanghai Vinnerna Biosciences Co., Ltd.

INDUSTRY

NCT05895812 - A Study in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function | Biotech Hunter | Biotech Hunter